SNDX — Syndax Pharmaceuticals Inc

Ownership history in MPM BioImpact LLC  ·  2 quarters on record

This page tracks every 13F SEC filing in which MPM BioImpact LLC reported a position in Syndax Pharmaceuticals Inc (SNDX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
3.46% (2025 Q3)
Avg. % of fund
3.34%
First filed
2025 Q3
Last filed
2025 Q4
Quarters held
2
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 1,337,702 -37,972 -2.8% 3.22% $28.1M $21.01
2025 Q3 INITIATED 1,375,674 — — 3.46% $21.2M $15.39
% of Fund (quarterly)    SNDX price (monthly, adj. close)

Other funds also holding SNDX

As of 2025 Q4 — sorted by position size

Elmind Capital, LP 11.5% Kynam Capital Management, LP 3Y 10.81% KINGDON CAPITAL MANAGEMENT, L.L.C. 3Y 7Y 5.87% Aisling Capital Management LP 3Y 7Y 5.78% STEMPOINT CAPITAL LP 4.83% Catalio Capital Management, LP 4.44% Knott David M Jr 3Y 4.04% Lion Point Capital, LP 3Y 7Y 3.91% Eversept Partners, LP 3Y 7Y 3.51% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 3.1%
← Back to MPM BioImpact LLC Holdings